Exclusive
New fund targets companies battered by market doubts
Jessica SierNorth Asia correspondent
A new venture capital fund aimed at funding cash-starved Australian medical, biotech and health technology start-ups has banked $40 million of a planned $200 million, as public valuations hit record lows.
Hashan De Silva, a biotech investor who cut his teeth as the first hire at private and public equity outfit Karst Peak, is hoping to take on cashed-up pharmaceutical giants as the first consolidation shoots begin to show.
Loading...
Subscribe to gift this article
Gift 5 articles to anyone you choose each month when you subscribe.
Subscribe nowAlready a subscriber?
Introducing your Newsfeed
Follow the topics, people and companies that matter to you.
Find out moreRead More
Latest In Technology
Fetching latest articles